PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 5, 20263 citations

Safety of Short-Term Trimethoprim-Sulfamethoxazole Use for Uncomplicated Cystitis: A Nationwide Retrospective Cohort Study.

View Full Paper
JTJumpei TaniguchiSAShotaro AsoHYHideo Yasunaga

Key Points

  • To evaluate the safety of short-term trimethoprim-sulfamethoxazole (TMP-SMX) use for uncomplicated cystitis compared to fluoroquinolones.
  • Conducted a nationwide retrospective cohort study in Japan
  • Compared adverse events and treatment failure rates between TMP-SMX and fluoroquinolones
  • Analyzed data from patients diagnosed with uncomplicated cystitis
  • No increased risk of adverse events observed with TMP-SMX compared to fluoroquinolones
  • Treatment failure rates were similar for both TMP-SMX and fluoroquinolones
  • TMP-SMX is suggested as a reasonable first-line option for acute uncomplicated cystitis

Abstract

Short-term use of TMP-SMX was not associated with increased risks of adverse events or treatment failure compared with fluoroquinolones. TMP-SMX may represent a reasonable first-line option for acute uncomplicated cystitis in Japan.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Taniguchi et al. (2026) studied this question.

synapsesocial.com/papers/69a91da8d6127c7a504c0b78https://doi.org/10.1002/pds.70342
Ask AI
Helpful
Bookmark
Share
View Full Paper